LeállítvaFázis nélkül
International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy
A legfontosabb adatok
- Ki végzi
- Johns Hopkins University
- Hol
- Szaúd-Arábia és Vietnám10 helyszín, 2 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Résztvevők
- 360 fő vett részt
- Kezdés
- 2022. ápr. 15.
- Befejezés
- 2025. jún. 7.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- GALAD Score
- A regiszteradat frissítve
- 2025. június 12.
- Miért állt le
- PI moving on from current institution
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
A regiszter feltételei, szó szerint
Mind a 32 feltétel megnézéseKevesebb
Ki vehet részt
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study and up to 5 years post-study follow up
- Adults aged 18 or older
- Both genders and all ethnicities
- Willingness to give written, informed consent to be enrolled into the database
- Collection of biosamples (serum, plasma, and urine) at each of the 6 months follow up during the study duration
- Individuals already confirmed to have cirrhosis with MELD ≤ 15 from any etiology (chronic HBV, chronic HCV, NASH cirrhosis, etc.)
- For chronic HBV and/or /HCV carrier, with or without on treatment
- Reside in Vietnam or Saudi Arabia at the time of study and provides contact information (email and/or cell phone number for texting)
- No prior or current treatment of HCC
- No cancer history within 5 years
- No participation in a trial for HCC Treatment
- No prior solid organ transplant
- Albumin, Bilirubin, Creatinine and INR labs within past 30 days
- Imaging showing no HCC within 180 days
- Diagnosis of fibrosis and cirrhosis based on: histology, image showing cirrhotic liver with splenomegaly and platelets <120 mm3, or esophageal or gastric varices on endoscopy AND presence of chronic liver disease/Fibroscan/Fib-4/APRI/ARFI. For viral hepatitis, kPa>=9kPa, APRI >=1; for NAFLD/NASH (FIB-4 > 1.3 \& TE > 8kPa)
- No significant hepatic decompensation
- No hepatorenal syndrome
- AFP labs within 180 days irrespective of AFP titer
- Two phone numbers and personal identification numbers (CMND number)
- No known AIDS related diseases
- No significant co-morbid conditions with life expectancy <5 years
- No other cancer(s)
Ki nem vehet részt
- On liver transplantation list or anticipated to be on the liver transplantation list during the study duration
- Taking Vitamin K within 7 days prior to clinic follow or having disease affecting Vitamin K levels
- Active drug use or dependence that, in the opinion of the study investigator, would interfere with adherence to study requirements
- Decompensated cirrhosis (variceal bleeding, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis, and/or hepatorenal syndrome) or MELD>15
- Any serious or active medical or psychiatric illness, which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol
- Known HIV positive
- Individuals who already have HCC, with or without HCC treatment
- Individuals who cannot, do not want to, or refused to sign the informed consent form (ICF)
- Documentation was not adequate
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study has two purposes. One is to conduct a phase IV biomarker validation study in which the investigators will prospectively survey a cohort of patients at risk for liver cancer using semi-annual abdominal ultrasound and GALAD Score for 5 years. The GALAD score is a serum biomarker-based panel that can aid in early detection among patients with a high risk for liver cancer. One is to establish a bio-repository of longitudinally collected bio-specimens from patients with fibrosis/cirrhosis as a reference set for future research.
A vizsgált kezelések
- GALAD Score
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Surveillance and Treatment Of Primary Hepatocellular Carcinoma: An International Cohort Study of High-Risk Patients for HCC Using Liquid Biopsy
- Publikációk
- A regiszteradat frissítve
- 2025. június 12.